The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection.
The names of the groups in this research study are:
* Group A: Prehabilitation program * Group B: Usual Care
Age greater than or equal to 18 years at time of enrollment.
English-Speaking.
Diagnosis of clinical stage II-III rectal cancer.
Planned, ongoing or just completed neoadjuvant treatment, including either 1) chemoradiation, 2) total neoadjuvant therapy (TNT), or 3) chemotherapy only; and anticipated surgical resection to follow.
Distant metastatic disease known at the time of diagnosis.
Functional incapacity (i.e., incapable of performing exercise testing).
Comorbid conditions or cognitive/physical impairments that contraindicate exercise.
Currently undergoing treatment for a secondary primary tumor, in addition to primary rectal cancer.
Dana-Farber Cancer Institute
Lead sponsor